Τhis study aims to assess changes in the fovea avascular zone (FAZ) in treatment naïve patients receiving aflibercept or ranibizumab injections for diabetic macular edema (DME). This is a prospective study recruiting patients with treatment-naïve DME. Best corrected visual acuity (BCVA) testing, OCT and OCT-angiography (OCTA) imaging were performed at baseline and 1 month after each injection. Injections of either aflibercept or ranibizumab were administered monthly for 6 consecutive months. FAZ in the superficial (SCP) and the deep capillary plexus (DCP) using OCTA was recorded for each visit. Fifty eyes from 50 patients with a mean age of 67.010.7 years were included in the study Twenty-five patients received aflibercept and 25 received ranibizumab. BCVA was 40.810.0 and increased to 52.17.9 ETDRS letters at the last visit (p<0.001). CRT was 295.634.0 at baseline and 247.929.7 at the last study visit (p<0.001). SCP FAZ was 350.679.5μm2 at baseline and 339.071.3μm2 after 6 monthly injections (p=0.132). DCP FAZ was 558.6199.0μm2 at baseline and 459.5156.1μm2 after 6 monthly injections (p<0.001). There was no effect of the choice of ranibizumab or aflibercept on DCP FAZ change (p=0.277). In conclusion, treatment with 6 monthly injections of ranibizumab and aflibercept led to an increase in BCVA and a decrease in CRT and DCP FAZ area. Both drugs led to an improvement in DCP ischemia.